The Hazelden Co-occurring Disorders Program features user-friendly components including clinician's guides and reproducible handouts in multiple formats. The program is published by Hazelden, the leading publisher of evidence-based curricula.

View Now a 8 minute Program Overview:

A new integrated treatment program developed by the faculty fom Dartmouth Medical School

Research shows the most effective treatment for co-occurring disorders is an integrated approach that treats both substance use and mental health disorders at the same time and in the same place.

CDP is the first innovative, comprehensive and multi-formatted program that provides the tools for integrated treatment services.

CDP is the first program that allows for customizing an approach to fit the addicted patient and his or her specific mental health problem.

CDP is more than evidence-based curricula, clinical manuals, a DVD, training, and Web content, all at an affordable price for cost-conscious treatment and mental health centers.

CDP also offers:

• effective customizable strategies to treat patients' specific co-occurring disorders,
• evidence-based strategies and standardized best practices for treatment, mental health, and criminal justice,
• tools to help sustain clinicians' confidence and skills to assess and treat patients' comorbid disorders,
• benchmarks to transform your addiction-only system (AOS) to dual diagnosis capable (DDC); or increase your DDC center to dual diagnosis enhanced (DDE treatment,
• manualized integrated treatment interventions which can facilitate the education and training of new staff for competency in treating both substance use and mental health disorders,
• a complete transparency in DVD content which allows clients and family members to access the same educational information offered to clinicians and other health care professionals, an approach that supports a key concept of effective treatment where all are equal shareholders in deciding on the best and most appropriate integrated treatment plan.
• screening and assessment measures to distinguish between drug-induce mental health problems and psychiatric morbidity and to help determine effective pharmacotherapy and psychosocial interventions